Generated by AI
Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Its current portfolio centers on Epstein-Barr virus (EBV)-targeted T-cell programs and next-generation CAR T candidates, reflecting a platform built to harness donor-derived immune cells for precision treatment approaches. The company’s product development activities include therapies aimed at EBV-driven diseases and B-cell malignancies, positioning it within the broader cell therapy and immuno-oncology markets. Headquartered in Thousand Oaks, California, Atara Biotherapeutics serves the evolving demand for advanced immunotherapies that can be manufactured and deployed without traditional patient-specific cell engineering.
Website1280 Rancho Conejo Blvd
Thousand Oaks, CA, 91320
United States
The latest articles about ATRA.
THOUSAND OAKS, Calif., October 14, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) resubmission for tabelecleucel,
Summary of May 12's posts. Generated by AI.
Summary of May 8's posts. Generated by AI.
Summary of Feb 26's posts. Generated by AI.
Summary of Apr 4's posts. Generated by AI.
Investors talking about ATRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.